Abbisko Deal History & Licensing Activity
Abbisko is a biotech headquartered in China. Over the past three years, Abbisko has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 22 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
22
Top Modality
Small Molecules
Focus Area
Solid Tumors
Abbisko Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Abbisko in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lumipodlin (ABSK043) | AstraZeneca | Small Molecules | Phase 2 | collaboration | Jul 1, 2026 |
| multitarget oncology programs | Eli Lilly | Small Molecules | Unknown | collaboration | Jun 24, 2026 |
Abbisko Pipeline Focus
Therapeutic areas and modalities where Abbisko is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Abbisko Clinical Pipeline
Abbisko has 22 active clinical trials across 4 development phases.
9
Phase 1
2
Phase 1/2
9
Phase 2
2
Phase 3
See How Your Asset Matches Abbisko's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Abbisko Licensing & Deal Activity
Abbisko is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Abbisko ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Abbisko include Solid Tumors (13 deals and trials), Oncology (4 deals and trials), and Musculoskeletal (1 deal and trial). In terms of modality, Abbisko has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Abbisko and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Abbisko's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.